Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04638829 · ClinicalTrials.gov registry record · Phase 4
Safety and Treatment Satisfaction in Adults With Chronic ITP After Switching to Avatrombopag From Eltrombopag or Romiplostim
A Phase 4 study of Immune Thrombocytopenia, sponsored by Sobi.
- Completed
- Registry status
- Phase 4
- Development phase
- 60
- Enrollment target
- 20
- Study locations
NCT04638829 is a Phase 4 study of Immune Thrombocytopenia that has completed, run by Sobi. The registered enrollment target is 60 participants, below the 114-participant average among 6 other Immune Thrombocytopenia trials with a reported enrollment target (47% lower). The trial reports 20 study locations across 14 states.
The verdict
NCT04638829, a Phase 4 study of Immune Thrombocytopenia, has completed, sponsored by Sobi.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 60 participants
- Enrollment target
- 20
- Study locations
Study Summary
Evaluate the safety and tolerability of avatrombopag given for 90 days after stopping treatment with eltrombopag or romiplostim.
Conditions Studied
Interventions
- DRUG Avatrombopag Oral Tablet
Study Locations (20)
Florida
- Sobi Site 129 - Miami
- Sobi Site 120 - Ocala
- Sobi Site 125 - St. Petersburg
- Sobi Site 118 - Tampa
Illinois
- Sobi Site 126 - Chicago
- Sobi Site 109 - Peoria
North Carolina
- Sobi Site 121 - Chapel Hill
- Sobi Site 116 - Greenville
Pennsylvania
- Sobi Site 127 - Philadelphia
- Sobi Site 102 - York
Arizona
- Sobi Site 110 - Tucson
California
- Sobi Site 119 - Whittier
District of Columbia
- Sobi Site 123 - Washington D.C.
Louisiana
- Sobi Site 124 - New Orleans
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 60 participants |
| Start Date | 2021-03-15 |
| Est. Completion | 2024-01-03 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04638829
The ClinicalTrials.gov registry entry for NCT04638829 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 60 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 114-participant average among 6 other Immune Thrombocytopenia trials with a reported enrollment target (47% lower). The listed sponsor is Sobi, which has 5 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Immune Thrombocytopenia appearing as the primary indexed condition, and to 1 intervention - of which Avatrombopag Oral Tablet is the first listed.
NCT04638829 reports 20 study locations spanning 14 distinct geographic areas - top geographies include Florida, Illinois, North Carolina.
Frequently Asked Questions
What is clinical trial NCT04638829 about?
NCT04638829 is a clinical study titled "Safety and Treatment Satisfaction in Adults With Chronic ITP After Switching to Avatrombopag From Eltrombopag or Romiplostim". Evaluate the safety and tolerability of avatrombopag given for 90 days after stopping treatment with eltrombopag or romiplostim.
What is the current status of trial NCT04638829?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 60 participants. The study started on 2021-03-15. Estimated completion is 2024-01-03.
What conditions does trial NCT04638829 study?
This clinical trial studies the following conditions: Immune Thrombocytopenia.
What interventions are being tested in trial NCT04638829?
The interventions under investigation include: Avatrombopag Oral Tablet (DRUG).
Who is sponsoring clinical trial NCT04638829?
This trial is sponsored by Sobi, which has 5 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04638829 being conducted?
This trial has 20 study locations across Arizona, California, District of Columbia, Florida, Illinois. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Immune Thrombocytopenia
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Study to Assess the Safety and Tolerability of Tafasitamab in Adult Participants With Primary Autoimmune Blood Cell Disorders
RECRUITING · Phase 2
-
Cognitive Dysfunction in Chronic and Persistent Immune Thrombocytopenia
RECRUITING
-
Study to Evaluate the Efficacy and Safety of Oral Rilzabrutinib in Adults With Immune Thrombocytopenia (ITP) Who Failed First-line Treatment
RECRUITING · Phase 3
-
An Open-label Study of Povetacicept in Participants With Autoimmune Cytopenias
ACTIVE NOT RECRUITING · Phase 1
-
Study to Evaluate Rilzabrutinib in Adults and Adolescents With Persistent or Chronic Immune Thrombocytopenia (ITP)
ACTIVE NOT RECRUITING · Phase 3
-
Long-term Study of Romiplostim in Thrombocytopenic Pediatric Patients With Immune Thrombocytopenia (ITP)
COMPLETED · Phase 3
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.